SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (591)3/10/2005 5:30:47 PM
From: olivier benrubi   of 946
 
Thanks. I should have read the protocols instead of just looking at the description of the trials :-( .
It is indeed tricky to find comprehensive statistics on the treatment being used.

Not sure if this is posted already somewhere mesothel.com

"Treatment of advanced non-small-cell lung cancer patients with
ECOG performance status 2: results of an European Experts Panel"

Results and conclusions: On the basis of current evidence, chemotherapy treatment appears justified for
patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could
be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative
options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients.
Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in
randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and
efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority
is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as
symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2
NSCLC patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News